Clinical Trials Logo
  1. Home
  2. Morphea
  3. NCT02411643

Molecular Effects of Topical Calcipotriene on Morphea

Morphea Clinical Trial

Official title:
Molecular Effects of Topical Calcipotriene on Morphea

Clinical Trial Summary

This study will look into how topical treatment with synthetic Vitamin D3, calcipotriene ointment, used as standard of care, works in patients with morphea. Skin biopsies of morphea lesions before and after treatment with topical calcipotriene 0.005% ointment will be analyzed for changes in RNA and protein. A skin biopsy of unaffected skin will also be obtained and used for a control. This is an initial study to look at the molecular effects of topical calcipotriene on human morphea-involved skin. This study will look at the differences between affected and unaffected skin. This study also will look at clinical outcomes in morphea patients and determine if there are any clinical predictors for improvement with the medication.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02411643
Study type Interventional
Source Northwestern University
Contact
Status Terminated
Phase Early Phase 1
Start date March 2015
Completion date April 2016
View Details
See also
  Status Clinical Trial Phase
Completed NCT03351114 - Pilot Study Evaluating the Efficacy of a Topical PDE4 Inhibitor for Morphea Phase 2
Completed NCT03630198 - Pain Outcomes Following Intralesional Corticosteroid Injections Phase 4
Withdrawn NCT00230373 - Imiquimod 5% Cream in Plaque-type Morphea: A Pilot, Prospective Open-label Study Phase 3
Completed NCT01799174 - Treatment Study Comparing UVA-1 Phototherapy Versus Placebo Treatment for Morphea N/A
Recruiting NCT01808937 - Morphea in Adults and Children (MAC) Cohort Study: A Morphea Registry and DNA Repository
Enrolling by invitation NCT04922736 - Patient Reported Outcomes With UVA-1 Therapy for Treatment of Sclerosing Skin Diseases N/A
Withdrawn NCT04656704 - Hyaluronidase in Treating Oral Microstomia in Patients With Sclerosing Skin Disease Early Phase 1
Completed NCT04752397 - The Influence of Extracorporeal Photopheresis on Skin Sclerosis
Terminated NCT03740724 - A Study of FCX-013 Plus Veledimex for the Treatment of Moderate to Severe Localized Scleroderma (Morphea) Phase 1/Phase 2
Completed NCT02222038 - Genetic Variants in Linear Localized Scleroderma N/A